Colorectal cancer (CRC) is one of the most malignant cancers in gastrointestinal tract. In China, there are increasing rates of morbidity and mortality for CRC. As the mortality is closely related to the stage of disease at time of diagnosis, early diagnosis of CRC is important. However, current techniques used for clinical diagnosis have limitations which made them difficult to achieve the early diagnosis. The detection of RNAs in stool is a newly developed noninvasive technique for early diagnosis of CRC at molecular levels. Compared with the techniques including colonoscopy, fecal occult-blood test and stool DNA-based mutation detection, diagnosis based on the detection of RNAs in stool has the advantages of low-cost and high sensitivity. Moreover, stool RNA-based techniques are able to analyze multiplexed gene expression simultaneously and monitor cancer progression dynamically. This paper introduced the feasibility of stool RNA analysis, and systematically reviewed the genes associated with stool RNA analysis, methods of RNA isolation from stool sample, and techniques for gene expression analysis in stool RNA. Finally, further applications of stool RNA-based techniques for early diagnosis of CRC were briefly discussed.
[1] Dodd GD. Epidemiology and economic impact of colon can-cer. American College of Radiology, 1990, 13.
[2] Kahi CJ, Imperiale TF, Juliar BE, Rex DK. Effect of screen-ing colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol, 2009, 7(7): 770–775.
[3] Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst, 1999, 91(5): 434–437.
[4] Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of cur-rent American cancer society guidelines and issues in cancer screening. CA Cancer J Clin, 2010, 60(2): 99–119.
[5] Huang J, Kirk B, Favis R, Soussi T, Paty P, Cao W, Barany F. An endonuclease/ligase based mutation scan-ning method especially suited for analysis of neoplastic tissue. Oncogene, 2002, 21(12): 1909–1921.
[6] Li M, Diehl F, Dressman D, Vogelstein B, Kinzler KW. BEAMing up for detection and quantification of rare se-quence variants. Nat Method, 2006, 3(2): 95–97.
[7] Zou H, Taylor WR, Harrington JJ, Hussain FT, Cao X, Loprinzi CL, Levine TR, Rex DK, Ahnen D, Knigge KL, Lance P, Jiang X, Smith DI, Ahlquist DA. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology, 2009, 136(2): 459–470.
[8] Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The consensus coding sequences of human breast and colorectal cancers. Science, 2006, 314(5797): 268–274.
[9] Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yama-moto S, Kozu T, Baba H, Matsumura Y. Detection of colo-rectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. Cancer Sci, 2008, 99(10): 1977–1983.
[10] Ahmed FE, Vos PW, Ijames S, Lysle DT, Flake G, Sinar DR, Naziri W, Marcuard SP. Standardization for transcriptomic molecular markers to screen human colon cancer. Cancer Genomics Proteomics, 2007, 4(6): 419–431.
[11] Juretzka MM, Jensen KC, Longacre TA, Teng NN, Husain A. Detection of pelvic lymph node micrometastasis in stage IA2-IB2 cervical cancer by immunohistochemical analysis. Gynecol Onco, 2004, 93(1): 107–111.
[12] Yang SH, Chien CC, Chen CW, Li SY, Huang CJ. Potential of faecal RNA in diagnosing colorectal cancer. Cancer Lett, 2005, 226(1): 55–63.
[13] Osborn NK, Ahlquist DA. Stool Screening for Colorectal Cancer: Molecular Approaches. Gastroenterology, 2005, 128(1): 192–206.
[14] Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN. Regula-tion of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem, 2000, 275(43): 33951–33956.
[15] Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Ishii Y, Endo T, Kabeshima Y, Yorozuya K, Yamamoto K, Mukai M, Kitajima M. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum, 2002, 45(1): 98–103.
[16] Wu AW, Gu J, Ji JF, Li ZF, Xu GW. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol, 2003, 9(9): 1990–1994.
[17] Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology, 2004, 127(2): 422–427.
[18] Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev, 2004, 23: 101–117.
[19] Takai T
